新型生物瓣膜手术植入治疗深静脉反流的三年结局
这项首次人体研究在哥伦比亚11例保守治疗无效的深静脉反流患者中手术植入VenoValve生物瓣膜,技术成功率100%。3年随访原发通畅率79%,反流时间平均减少62%,修订版静脉临床严重程度评分降低7分(52%),疼痛视觉模拟评分降低84%。结论认为该瓣膜在难治性血栓后综合征中显示出中期安全性和有效性,但可能需要长期抗凝以维持获益。
要点
- VenoValve植入技术成功率100%,3年原发通畅率79%。
- 3年随访反流时间平均减少62%,修订版VCSS降低7分(52%),VAS疼痛降低84%。
- 2例发生瓣膜血栓,均在停用抗凝后;未观察到严重器械相关不良事件。
核心结论
- VenoValve植入在难治性血栓后综合征患者中显示出恢复深静脉瓣膜功能的中期安全性和有效性,带来3年持续改善和疾病稳定。
- 长期抗凝治疗可能是维持这些获益所必需的。
- 这项首次人体研究为器械性能提供了证据,为监管审议提供信息,并支持在美国正在进行的 pivotal 试验中在更大队列中进一步评估。
研究设计与样本
- 首次人体研究,在哥伦比亚开展,植入VenoValve于股静脉。
- 纳入保守治疗无效且腘静脉深静脉反流≥1秒的血栓后综合征患者11例(男5例、女6例,平均年龄67±14.8岁)。
- VenoValve为10 mm×21 mm单瓣生物瓣膜,由猪主动脉壁和無冠主动脉瓣叶制成,缝在不锈钢框架上。
- 分析并报告技术结果和3年临床结局。
主要发现
- 2019年2月至12月期间,11例患者接受手术植入,技术成功率100%。
- 所有患者均有血栓后改变的临床和超声证据,6例(55%)自报有深静脉血栓病史。
- 按临床-病因-解剖-病理生理分类,6例(55%)为C6,5例(45%)为C5。
- 3例在1年后失访;3年随访时VenoValve原发通畅率为79%。
- 患者反流时间平均减少62%,修订版静脉临床严重程度评分平均降低7分(52%),疼痛视觉模拟评分平均降低84%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 3例患者在1年后失访。
- 2例瓣膜血栓均发生在停用抗凝后,长期抗凝治疗可能是维持获益所必需的。
- 这是一项首次人体研究,支持在美国正在进行的 pivotal 试验中在更大队列中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic venous insufficiency (CVI) affecting the deep venous system is most often caused by postthrombotic syndrome (PTS), which leads to reflux, blood pooling, and venous hypertension in the lower extremities. Researchers have sought to restore deep valvular competence, with numerous attempts at primary repair and valve replacement yielding limited results. This article presents the mid-term outcomes (3 years) of the first-in-human study of the bioprosthetic VenoValve surgically implanted in patients with CVI. METHODS: The VenoValve is a 10-mm × 21-mm monocusp bioprosthetic valve crafted from porcine aortic wall and noncoronary aortic valve leaflet, sewn onto a stainless-steel frame and designed to restore deep venous competence. In a first-in-human study conducted in Colombia, the VenoValve was implanted in patients with PTS unresponsive to conservative management and with deep venous reflux ≥1 sec, measured at the popliteal vein. Technical results and 3-year clinical outcomes were analyzed and reported. RESULTS: Between February and December 2019, 11 patients (5 males and 6 females; mean age 67 ± 14.8) underwent surgical implantation of the valve in the femoral vein. All patients had clinical and sonographic evidence of postthrombotic changes, and a self-reported history of deep venous thrombosis was positive in 6 patients (55%). According to the clinical, etiologic, anatomic, and pathophysiologic classification, 6 patients (55%) were classified as C6, and 5 patients (45%) were classified as C5. The technical success rate was 100%. Three patients were lost to follow-up after 1 year. At the 3-year follow-up, the VenoValve showed a primary patency rate of 79%, with patients experiencing a mean reduction of 62% in reflux times, 52% in the revised Venous Clinical Severity Score (7-point reduction), and 84% in pain levels (visual analog scale). Valve thrombosis occurred in 2 patients, 1 at 3 months and the other at 3 years postimplantation; both events occurred after the patient discontinued anticoagulation. No serious device-related adverse events were observed. CONCLUSION: VenoValve implantation demonstrated mid-term safety and efficacy in restoring deep venous competence in patients with refractory PTS, leading to sustained improvement and stabilization of the disease for 3 years. Nonetheless, long-term anticoagulation therapy may be necessary to maintain these benefits. This first-in-human study provides evidence of the device's performance, informing regulatory deliberations and supporting further evaluation in a larger cohort in an ongoing pivotal trial in the United States.
引用
- Cifuentes S, Figueroa AV, Glickman MH, et al. Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve for the Treatment of Deep Venous Reflux. Ann Vasc Surg. 2025. PMID: 40252802. doi:10.1016/j.avsg.2025.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。